Table 1.
Baseline characteristics.
| No web (n = 1436) | Carotid web (n = 27) | P‐value | |
|---|---|---|---|
| Age, median (IQR) | 74 (62–84) | 60 (53–67) | <0.001 |
| Male sex | 698 (48.6%) | 11 (40.7%) | 0.42 |
| Race | |||
| White | 1140 (79.4%) | 16 (59.3%) | 0.014 |
| Black | 71 (4.9%) | 5 (18.5%) | |
| Asian | 16 (1.1%) | 0 (0.0%) | |
| Other | 209 (15%) | 6 (11%) | |
| Hispanic ethnicity | 81 (5.6%) | 3 (11.1%) | 0.48 |
| Hypertension | 1087 (75.7%) | 15 (55.6%) | 0.05 |
| Diabetes mellitus | 357 (24.9%) | 7 (25.9%) | 0.96 |
| Hyperlipidemia | 776 (54.0%) | 14 (51.9%) | 0.95 |
| Atrial fibrillation | 600 (41.8%) | 8 (29.6%) | 0.43 |
| NIHSS, median (IQR) | 17 (11–21) | 16 (11–21) | 0.81 |
| Symptomatic web location | |||
| Right | 19 (70.4%) | ||
| Left | 8 (29.6%) | ||
| IV thrombolytics | 565 (39.4%) | 16 (59.3%) | 0.037 |
| Medications at baseline | |||
| Aspirin | 493 (34.3%) | 10 (37.0%) | 0.88 |
| Clopidogrel | 76 (5.3%) | 0 (0.0%) | |
| Direct oral anticoagulant | 144 (10.0%) | 0 (0.0%) | 0.65 |
| Warfarin | 112 (7.8%) | 0 (0.0%) | 0.86 |
| Location of occlusion | |||
| ICA | 267 (18.6%) | 5 (18.5%) | 0.50 |
| M1 | 921 (64.1%) | 21 (77.8%) | |
| M2 | 248 (17.3%) | 1 (3.7%) | |
| Mechanism | |||
| Cardioembolism | 606 (45.8%) | 6 (23.1%) | <0.01 |
| LAA | 206 (15.6%) | 2 (7.7%) | |
| ESUS | 380 (28.7%) | 18 (69.2%) | |
| Stroke of other etiologies | 129 (9.8%) | 0 | |
Values are expressed as n (%). IQR, interquartile range; NIHSS, National Institute of Health Stroke Scale; DOACs, direct oral anticoagulants.